Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rimonabant (SR141716) Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

NCT00459173
View directory record Official record
Conditions
Maintenance of Smoking Cessation
Interventions
rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

NCT00481975
View directory record Official record
Conditions
Obesity, Eating Disorders
Interventions
rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Obese Patients With Type 2 Diabetes

NCT00029848
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Non-Insulin-Dependent, Obesity in Diabetes
Interventions
Rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

NCT00299325
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Rimonabant, Placebo (for Rimonabant), Mild hypocaloric diet
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

NCT00257257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

NCT00458718
View directory record Official record
Conditions
Smoking Cessation
Interventions
rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

NCT00656487
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal
Interventions
rimonabant, placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
21 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

NCT00449605
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Glimepiride, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

NCT00547118
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension, Smoking
Interventions
Rimonabant, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

NCT00576667
View directory record Official record
Conditions
Fatty Liver
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

NCT00690456
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Placebo (for Rimonabant), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Antagonist-Elicited Cannabis Withdrawal

NCT01041170
View directory record Official record
Conditions
Cannabis, Dependence
Interventions
THC, Rimonobant, Rimonabant
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 4:22 PM EDT
Withdrawn Phase 3 Interventional

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

NCT00754689
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Metformin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

NCT00325650
View directory record Official record
Conditions
Prediabetic State
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
2,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

NCT00464256
View directory record Official record
Conditions
Smoking Cessation
Interventions
rimonabant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

NCT00358228
View directory record Official record
Conditions
Smoking Cessation
Interventions
Rimonabant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

NCT00263042
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
18,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Brain Imaging of Cannabinoid Receptors

NCT03204305
View directory record Official record
Conditions
Cannabis Use Disorder, Cannabis Dependence, Continuous
Interventions
11C-OMAR, Cannabis
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Rimonabant to Reduce Alcohol Consumption

NCT00075205
View directory record Official record
Conditions
Healthy, Alcohol Drinking
Interventions
SR141716 (Rimonabant)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148
View directory record Official record
Conditions
Fatty Liver
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 1, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

NCT00239967
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 1, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176
View directory record Official record
Conditions
Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 1, 2026, 4:22 PM EDT